Updates and Events
Lupus Research Alliance Announces 2019 Distinguished Innovator Awards Aimed at New Lupus Treatments

NEW YORK, October 24 — The Lupus Research Alliance proudly announces two exceptional recipients of the 2019 Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity:  Fabienne Mackay, PhD, and Jeffrey Rathmell, PhD. The highly prestigious up-to-$1 million grant will allow each investigator to test promising approaches for potential new lupus treatments. Dr. Mackay […] READ MORE

Lupus Research Alliance Welcomes New Senior Director of Marketing and Communications

NEW YORK, NY. October 16 — The Lupus Research Alliance (LRA) is pleased to announce that seasoned professional Penny Mitchell has joined the organization as Senior Director of Marketing and Communications. In her new role, Ms. Mitchell will oversee the organization’s strategic communications approach to leading lupus research worldwide and the value of participation by […] READ MORE

Peer-to-Peer Involvement Advances Scientific Exploration

Many dynamics of lupus contribute to the fact that its complexities have eluded the scientific community—but new hope may come from patients themselves. This is why Lupus Therapeutics piloted the Patient Advocates for Lupus Studies (PALS) program in the Summer of 2019. PALS focuses on reaching diverse populations to improve their knowledge and awareness of […] READ MORE

2023 United Airlines New York City Half-Marathon

March 19, 2023 marks the return of the United Airlines NYC Half Marathon. The Lupus Research Alliance Team Life Without Lupus® could not be more proud and excited to take part in this annual event. Join our Team and apply here for one of LRA’s Guaranteed Spots READ MORE

Epilepsy in People with Lupus

October 17, 2019 A new study published in the European Journal of Neurology showed that epilepsy is significantly more common among people with systemic erythematosus lupus (SLE) than the general population. According to the Epilepsy Foundation, epilepsy is a neurological disorder characterized by unpredictable seizures. A seizure is a sudden surge of electrical activity in […] READ MORE

Why Don’t Half of People with Lupus Take Hydroxychlorine As Prescribed?

October 3, 2019 Hydroxychlorine is one of the most common treatments for lupus.  But a new study published in The Journal of Rheumatology looked at why about half of people with lupus do not take hydroxychlorine as prescribed by their healthcare provider. The study looked at 1956 lupus patients 18 years or older being treated […] READ MORE

2019 Breaking Through Gala

The Lupus Research Alliance celebrates our annual Breaking through Lupus Gala on November 25, 2019 at the Ziegfeld Ballroom – an iconic landmark mingling up-to-the-moment elegance with the art-deco grandeur of 1920’s movie palaces. This year we are proud to honor Alfred F. Kelly, Chairman and Chief Executive Officer, Visa Inc. and Molly McCabe, Co-Founder, […] READ MORE

LRA Pleased to Share News of Lupus Nephritis Clinical Trial Launch

October 1, 2019 The Lupus Research Alliance is pleased to share news about the launch of EQUALISE, a Phase 1b trial that will evaluate the safety and tolerability of an experimental compound itolizumab at various doses in a small group of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Sponsored by the biotechnology company […] READ MORE

Nearly One-third of People with Lupus Treat Their Pain with Opioids

September 26, 2019 In a newly published Michigan study, nearly 1 in 3 adults with systemic lupus erythematosus used prescription opioids to treat pain despite lack of evidence that opioids effectively reduce pain from lupus and rheumatic diseases. As people with lupus know only too well, symptoms of the disease commonly include pain in the […] READ MORE

Accelerating Medicines Partnership Completes Key Phase

September 24, 2019 The Accelerating Medicines Partnership (AMP) RA/Lupus Program, a joint effort involving the National Institutes of Health (NIH), the Foundation for NIH, pharmaceutical companies, and non-profit organizations such as the Lupus Research Alliance, has reached a milestone, finishing an important phase of its studies. Researchers with the AMP RA/Lupus Program have published a […] READ MORE

Low-Dose Interleukin-2 Might be Effective for Lupus

September 24, 2019 Interleukin-2 at a low-dose may be effective in treating lupus, according to newly published results of a double-blind and placebo-controlled clinical trial. In this trial, 60 patients received either Interleukin-2 at a low dose of 1 million IU or placebo along with standard treatment for 12 weeks.  The primary endpoint – the […] READ MORE

Learn and connect with our community!